UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 18, 2015
Versartis, Inc.
(Exact name of registrant as specified in its charter)
Delaware | | 001-36361 | | 26-4106690 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | | |
4200 Bohannon Drive, Suite 250 Menlo Park, California | | 94025 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (650) 963-8580
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01Other Events.
On September 18, 2015, Versartis, Inc. (the “Company”) issued a press release announcing additional data from its ongoing Extension Study of somavaratan in pre-pubertal GHD children. A copy of the press release, titled “Versartis Announces Confirmatory 18-Month Data from Ongoing Extension Study of Somavaratan in GHD Children” is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | | Description | |
99.1 | | Press release dated September 18, 2015, titled “Versartis Announces Confirmatory 18-Month Data from Ongoing Extension Study of Somavaratan in GHD Children” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 18, 2015 | | Versartis, Inc. |
| | | |
| | By: | | /s/ Joshua T. Brumm |
| | | | Joshua T. Brumm |
| | | | Chief Financial Officer |
INDEX TO EXHIBITS
Exhibit No. | | Description | |
99.1 | | Press release dated September 18, 2015, titled “Versartis Announces Confirmatory 18-Month Data from Ongoing Extension Study of Somavaratan in GHD Children” |
| | |
